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Abstract
Epstein–Barr virus (EBV) infection in pregnancy and consequent fetal outcomes are rarely reported. The
majority of cases described strongly support the possibility of transmission of this virus in utero and during
delivery, resulting in stillbirth and/or congenital defects. We present a case of EBV reactivation in pregnancy
that caused a severe symmetrical fetal growth restriction (FGR) and ultimately spontaneous fetal death. A
36-year-old woman, whose infection status was undetermined, was diagnosed with severe FGR at 24 weeks’
gestation. The fetal karyotype was normal. EBV DNA was detected in the amniotic ﬂuid and maternal
immunoglobulin G antibodies were positive. At 30 weeks’ gestation, the fetus died spontaneously. Placental
examination found evidence of deciduitis and villitis. Reactivation of EBV infection appears to be related to
FGR and warrants further research to determine the optimal management strategy in pregnancy.
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Introduction
Epstein–Barr virus (EBV) is a herpes virus that infects
more than 90% of asymptomatic people.1 If the indi-
vidual is infected during adolescence and adulthood,
EBV can cause a benign lymphoproliferative disease
known as infectious mononucleosis.2 In pregnancy,
similarly to cytomegalovirus (CMV), varicella zoster
virus and human herpes virus (HHV) types 6, 7 and 8,
EBV shares the ability to establish latency, but can
become reactive at a later time.3 Structural fetal abnor-
malities can result from intrauterine infection and
transmission of the infection during pregnancy, and
transmission by blood at the time of delivery may
result in neonatal disease.3
However, EBV-related pregnancy outcome data is
conﬂicting regarding adverse outcomes: according to
Eskild et al., while pregnancy is a state of altered immu-
nity, it is not associated with increased EBV reactiva-
tion, and thus there is no association between EBV
antibody status and fetal death.4 Haeri et al. reported on
EBV reactivation as a biological marker of stress in
pregnancy, since there is mounting evidence that stress
promotes latent EBV reactivation in non-pregnant adult
populations (with a rate of 20–30%).5 In addition,
although cases of birth defects, prematurity and low
birth weight have been observed, they could not be
deﬁnitively linked to EBV infection.2 Case reports and
studies of EBV in amniotic ﬂuid suggest that in utero
infection does indeed occur.2,6 A study by Meyohas
et al. determined that a signiﬁcant reactivation of EBV
infection in the ﬁrst part of pregnancy was associated
with earlier delivery and lower birth weight in still-
born and live-born children.2
This case report of the presence of EBV in amniotic
ﬂuid, symmetric fetal growth restriction (FGR) and
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fetal demise, gives a further example of the conse-
quences of EBV in pregnancy. In the light of the pub-
lished research described above, this report indicates
the need for further investigation into the conse-
quences of maternal EBV infection during pregnancy.
Materials and Methods
A quantitative real-time polymerase chain reaction
(PCR) (Bio-Rad Laboratories, Philadelphia, PA, USA)
was applied for amniotic ﬂuid. A multicolor real-time
PCR has been used with the following ﬂuorophores
containing DNA probes (TaqMan probe; IDT, San Jose,
CA, USA):
• Fluorophore containing Fam for detecting EBV, toxo-
plasmosis, parvovirus B19, adenovirus and tre-
ponema DNA
• Fluorophore containing Hex for detecting CMV
DNA
• Fluorophore containing Cy5 for detecting HHV
DNA.
We quantiﬁed the number of copies of DNA virus
based on three standard levels: S1, 10 000 copies/mL;
S2, 1000 copies/mL; and S3, 100 copies/mL.
Case Report
A 36-year-old woman, gravida 2, para 1, attended
routine follow up for her pregnancy at 24 weeks’ ges-
tation, at which time the fetus was diagnosed with
FGR. The obstetric history of this pregnant woman was
unremarkable with no abortion, fetal and/or child
malformation. Her ﬁrst daughter had been delivered in
2005 by cesarean section at term. There was no evi-
dence of infection in the ﬁrst trimester, conﬁrmed by
laboratory tests, which were negative for toxoplasmo-
sis, CMV, rubella, hepatitis B virus, human immunode-
ﬁciency virus (HIV) and syphilis.
Fetal development was normal until the 24th week of
gestation: the fetal nuchal translucency thickness was
1.1 mm (crown rump length = 50 mm) and the possi-
bilities of trisomy 21 and 18 were calculated using a
combined test as 1/398 and 1/20 176, respectively. At
the 24th week of gestation, routine morphological scan-
ning showed the presence of hyperechoic bowel (grade
2) and symmetrical FGR. Doppler velocimetry of the
uterine artery was normal, there was no notch sign
(resistance index [RI] = 0.55 in left uterine artery and
RI = 0.47 in the right uterine artery) (Fig. 1), and an
absence of end-diastolic frequencies was diagnosed in
the umbilical artery (Fig. 2). Doppler velocimetry of
the middle cerebral artery and ductus venous were
normal (Figs 3,4).
The patient and her husband gave their consent for
amniocentesis to diagnose fetal chromosomal aberra-
tions. The fetal karyotype was conﬁrmed to be normal
(Fig. 5). Toxoplasmosis, parvovirus, adenovirus, tre-
ponema, CMV, HHV 1 and 2, and EBV were routinely
screened by using antibody measurements in the
maternal blood and real-time PCR in the amniotic
ﬂuid. EBV was incidentally detected in the amniotic
ﬂuid, with 26 800 copies/mL. The patient was then
further tested for EBV, and it was demonstrated to be
present in her peripheral blood: immunoglobulin
(Ig)G antibodies to the EBV capsid antigen were
Figure 1 Normal left and right uterine arteries at 24 weeks’ gestation (no notch sign).
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positive (174 IU/mL), and IgM antibodies were
negative.
After informed consent, the patient and her
husband preferred to pursue the pregnancy for as
long as possible. Fetal growth was reviewed every
two weeks by measurement of biparietal diameter
(BPD), head circumference (HC), femur length (FL)
and abdominal circumference (AC). All fetal biomet-
ric parameters were consistently found to be lower
than the third percentile line (Fig. 6). Doppler veloci-
metry of the umbilical artery, the middle cerebral
artery, and the ductus venous were performed
routinely every two weeks. There was a consistent
absence of end-diastolic frequencies in the umbilical
artery, the pulsatility index (PI) of middle cerebral
artery was found to be below the third percentile
(Fig. 7) and the ductus venous continued to show a
normal a-wave.
At the 30th week of gestation, the fetus demised spon-
taneously in utero, and after an induced labor, the
patient delivered a female infant transvaginally. The
stillborn baby weighed 900 grams and the placenta was
small, weighing 200 grams. Histopathological exami-
nation of placental tissues demonstrated deciduitis and
villitis with a signiﬁcant mononucleocyte inﬁltration,
trophoblastic necrosis and capillary endothelial
damage. The couple refused an autopsy for religious
Figure 2 Absent end-diastolic frequencies in the umbili-
cal artery. This sign was consistent from the 24th to the
30th weeks of pregnancy.
Figure 3 Normal Doppler velocimetry of the middle
cerebral artery at 24 weeks’ gestation (no notch sign,
normal pulsatility index [PI] and resistance index [RI]).
Figure 4 Normal Doppler velocimetry of the ductus
venous at 24 weeks’ gestation (normal a-wave, normal
pulsatility index [PI] and resistance index [RI]).
Figure 5 Normal fetal karyotype (46, XX).
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reasons, further histopathological and immunohis-
tochemical testing is not currently possible in our
resource-limited setting.
Discussion
This case report demonstrates symmetrical FGR and
early intrauterine death as apparent consequences of
reactivation of EBV infection in pregnancy. There is
very little known about maternal EBV infection and
pregnancy outcomes, since most published material
are case reports: some reported cases suggest a rela-
tionship between EBV and congenital heart disease,7,8,9
and FGR and multiple congenital anomalies;10,11 others
support the concept that entry of a viral genome into
the amniotic ﬂuid occurred in normal pregnancies
without any perinatal impacts.12 With evidence of a
poor fetal outcome and proven EBV infection in preg-
nancy, we think that EBV infection during pregnancy
may indeed produce an effect on perinatal and neonatal
outcomes.
Eskild et al. consider that adverse pregnancy out-
comes are not associated with EBV reactivation.4
Despite this conclusion, evidence has accumulated in
the last few years highlighting the complexity of the
interaction between EBV and the human host.13 The
Figure 6 Development of fetal biometry (biparietal diameter, head circumference, femur length and abdominal circumfer-
ence) from the 18th to the 30th weeks of gestation. All parameters were found to be below the third percentile line.
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actual damage to the developing embryo or fetus from
maternal herpes simplex virus and EBV appears to be
very small.14,15 But both herpes simplex virus and EBV
seem to be able to cross the placenta and cause, as
described by several investigators, placental infection
manifested by deciduitis and villitis. These placental
changes potentially cause fetal damage: Brown and
Stenchever reported on an infant exposed to EBV from
conception to delivery: the infant was delivered at
42 weeks’ gestation weighing 1720 g, showing sym-
metrical growth retardation and died several minutes
after delivery; post-mortem examination revealed mul-
tiple anomalies of the craniofacial complex, kidneys,
lungs, heart and brain.7 This case demonstrates that
EBV may cross the placenta causing placental and fetal
infection.10,15
In our case report, reactivation of EBV infection
during pregnancy was suggested because of a presence
of a high titer of IgG antibodies in maternal peripheral
blood (17 times higher than our laboratory cut-off
[10 IU/mL]) and real-time PCR evidence of EBV DNA
in the amniotic ﬂuid. In addition, the IgM antibody
titer was negative, so there was no evidence of a
primary infection. We propose that the impact of EBV
was to disrupt placental development, which then
caused a symmetrical FGR and an absence of end-
diastolic frequencies in the umbilical artery, and ﬁnally
fetal demise. We are limited in not being able to give
more certain evidence of EBV reactivation through his-
topathology and immunohistochemistry testing of the
placenta; however, this case is consistent with the
study of Eskild et al., who demonstrated that a reacti-
vation of EBV infection is associated with lower birth
weight in stillborn and live-born children.4
There is no published evidence in the literature that
EBV has an effect on the developing embryo or
fetus.5,15,16 Similarly, in this case, we found that the fetal
karyotype was normal (46, XX) and no fetal structural
abnormality was detected on ultrasonography. We also
conclude that EBV reactivation during pregnancy does
not represent a major teratogenic risk to the fetus as
Miller et al. afﬁrmed.12
However, there is a need for further studies to verify
the actual impact of EBV exposure on the fetus itself
during pregnancy. In the majority of the cases describ-
ing the inﬂuence of maternal EBV infection on preg-
nancy outcome, there seems to be placental, cardiac
and visual involvement.7,8,10,11,15,16 Avgil et al. found two
cases of congenital heart anomalies (ventricular septal
defect and persistent foramen ovale) in women who
had a recurrent EBV infection during the ﬁrst trimester
of pregnancy.16 They ruled out the possible association
of congenital heart disease and an exposure to EBV
from conception to delivery.16 Recently, Werler et al.
demonstrated that EBV reactivation resulting from
multiple challenges to the immune response, such as
pregnancy, age and toxic exposure might be related to
a risk of gastroschisis.17 Therefore, they propose further
research into gastroschisis caused by EBV and other
herpes viruses. The role of EBV in pregnancy, accord-
ing to Haeri et al., should be examined.5
Although reports of pregnant women with EBV
are rare,15 EBV infection in pregnancy does seem to
have a close relationship with stillbirth and congenital
defects.10 Our results support the studies that dem-
onstrate an association between EBV reactivation
and placental damage during pregnancy.10,11,13,16 We do
not recommend adding EBV testing in the universal
TORCH (toxoplasmosis, rubella, cytomegalovirus,
herpes simplex and HIV) screening for infection
during pregnancy, because the seroprevalence of this
virus is very rare in this population. Our message in
this case report is that the obstetricians should be aware
of the need for testing EBV infection during speciﬁc
pregnancies when trying to elucidate the possible
cause of early fetal growth restriction and/or intrauter-
ine death. We acknowledge that these ﬁndings need
conﬁrmation through future studies for prognosis of
pregnancy with EBV infection.
Figure 7 Abnormal pulsatility index (PI) curve of the
middle cerebral artery.
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